Byrne Asset Management LLC Arcutis Biotherapeutics, Inc. Transaction History

Byrne Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Jan 29, 2025	BUY	$8.32 - $11.0 $832 - $1,100	100 New	100 $0
Q3 2024 Jan 28, 2025	BUY	$8.32 - $11.0 $832 - $1,100	100 New	100 $0
Q2 2023 Jul 21, 2023	SELL	$7.51 - $15.0 $751 - $1,500	-100 Reduced 50.0%	100 $0
Q1 2022 Apr 05, 2022	BUY	$14.38 - $22.79 $2,157 - $3,418	150 Added 300.0%	200 $4,000
Q4 2021 Feb 22, 2022	BUY	$14.98 - $25.5 $749 - $1,275	50 New	50 $1,000

200

129M

738K

82K

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $748M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Byrne Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Byrne Asset Management LLC with notifications on news.